Akero Therapeutics, Inc.2025财年第一财季实现净利润-70.73百万美元，同比减少32.60%

市场透视05-19

5月19日，Akero Therapeutics, Inc.（AKRO.US）公布财报，公告显示公司2025财年第一财季净利润为-70.73百万美元，同比减少32.60%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Akero Therapeutics, Inc.（AKRO.US）总负债72.00百万美元，其中短期债务7.31百万美元，资产负债比为0.17，流动比率...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536594115?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536594115","market":"us","top_or_hot":-1,"title":"Akero Therapeutics, Inc.2025财年第一财季实现净利润-70.73百万美元，同比减少32.60%","media":"市场透视","content":"<div>\n<p>5月19日，Akero Therapeutics, Inc.（AKRO.US）公布财报，公告显示公司2025财年第一财季净利润为-70.73百万美元，同比减少32.60%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Akero Therapeutics, Inc.（AKRO.US）总负债72.00百万美元，其中短期债务7.31百万美元，资产负债比为0.17，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000141a482f007&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics, Inc.2025财年第一财季实现净利润-70.73百万美元，同比减少32.60%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics, Inc.2025财年第一财季实现净利润-70.73百万美元，同比减少32.60%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000141a482f007&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Akero Therapeutics, Inc.（AKRO.US）公布财报，公告显示公司2025财年第一财季净利润为-70.73百万美元，同比减少32.60%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Akero Therapeutics, Inc.（AKRO.US）总负债72.00百万美元，其中短期债务7.31百万美元，资产负债比为0.17，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000141a482f007&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000141a482f007&s=b","article_id":"2536594115","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000141a482f007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536594115","pubTimestamp":1747584036,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Akero Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-70.73百万美元，同比减少32.60%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Akero Therapeutics, Inc.总负债72.00百万美元，其中短期债务7.31百万美元，资产负债比为0.17，流动比率为0.17。机构评级：截至2025年5月19日，当前有12家机构对Akero Therapeutics, Inc.目标价做出预测，其中目标均价为73.83美元，其中最低目标价为49.00美元，最高目标价为109.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"AKRO":"Akero Therapeutics","LENZ":"Therapeutics"},"translate_title":"Akero Therapeutics, Inc. achieved net profit of-70.73 million in the first fiscal quarter of fiscal 2025, a year-on-year decrease of 32.60%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1,"LENZ":1},"content_text":"5月19日，Akero Therapeutics, Inc.（AKRO.US）公布财报，公告显示公司2025财年第一财季净利润为-70.73百万美元，同比减少32.60%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Akero Therapeutics, Inc.（AKRO.US）总负债72.00百万美元，其中短期债务7.31百万美元，资产负债比为0.17，流动比率为0.17。机构评级：截至2025年5月19日，当前有12家机构对Akero Therapeutics, Inc.目标价做出预测，其中目标均价为73.83美元，其中最低目标价为49.00美元，最高目标价为109.00美元。公司简介：Akero Therapeutics Inc是一家临床阶段的生物技术公司，致力于开发和商业化针对医疗需求高度未得到满足的严重代谢疾病的变革性治疗。它专注于非酒精性脂肪性肝炎(NASH)，一种没有任何批准疗法的疾病。该公司的候选产品efruxifermin是一种FGF21类似物，其特性有可能解决非酒精性脂肪性肝炎(NASH)发病机制的核心过程。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536594115","isCrawlerRequest":true}